| oxaliplatin / Generic mfg. |
NCT00826800: Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Terminated | N/A | 2 | US | FOLFOX and bevacizumab | Memorial Sloan Kettering Cancer Center, Genentech, Inc. | Colon Cancer | 01/11 | 01/11 | | |
NCT01339832: An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 51 | Europe | | Hoffmann-La Roche, Sanofi | Colorectal Cancer | 12/11 | 12/11 | | |
NCT01134666: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Terminated | N/A | 165 | RoW | Cetuximab, Erbitux | Merck KGaA, Darmstadt, Germany, Merck Ltd., India | Colorectal Neoplasms | 07/13 | 08/14 | | |
NCT00462501: Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 35 | US | bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Genentech, Inc. | Colorectal Cancer | 02/14 | 02/14 | | |
NCT01399190: An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer |
|
|
| Completed | N/A | 68 | Europe | Bevacizumab, Avastin®, Capecitabine, Xeloda®, Oxaliplatin, Eloxatin™ | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
NCT01801085: Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens |
|
|
| Terminated | N/A | 21 | RoW | | Vivian Wing Yan Lee, Hoffmann-La Roche, Queen Elizabeth Hospital, Hong Kong, Princess Margaret Hospital, Hong Kong | Colorectal Cancer | 12/14 | 12/14 | | |
NCT01442155: An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer |
|
|
| Completed | N/A | 74 | Europe | Capecitabine, Xeloda, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 04/15 | 04/15 | | |
SIRFLOX, NCT00724503: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer |
|
|
| Completed | N/A | 530 | US, Europe, RoW | SIR-Spheres yttrium-90 microspheres, mFOLFOX6m + SIRT, SIR-Spheres Y-90 microspheres, Systemic chemotherapy (FOLFOX), mFOLFOX6 | Sirtex Medical | Colorectal Cancer, Colorectal Carcinoma, Liver Metastases | 05/15 | 05/15 | | |
|
|
|
|
NCT01506167: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) |
|
|
| Completed | N/A | 719 | Europe | Bevacizumab, Avastin®, Capecitabine/Oxaliplatin, Fluorouracil/Folinic Acid/Oxaliplatin, Capecitabine, Fluorouracil/Folinic Acid/Irinotecan, Fluorouracil +/- Folinic Acid | Hoffmann-La Roche | Colorectal Cancer | 03/17 | 03/17 | | |
AVACONT, NCT02305615: An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC) |
|
|
| Completed | N/A | 300 | Europe | Bevacizumab, Avastin, Chemotherapy | Hoffmann-La Roche | Colorectal Cancer | 12/17 | 12/17 | | |
